Trofinetide (100mg)
Synthetic IGF-1 Tripeptide Analog — Approved for Rett Syndrome
Trofinetide (NNZ-2566) is listed for tripeptide neurobiology research. Catalog vial contents are 100mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Synthetic IGF-1 N-terminal tripeptide analog
- FDA-approved for Rett syndrome (DAYBUE®, 2023)
- Orally bioavailable small molecule
- CNS-active neurotrophic research compound
What is Trofinetide (NNZ-2566)?
A synthetic analog of the N-terminal tripeptide of IGF-1 (glycyl-L-prolyl-L-glutamate, GPE) — the first and only FDA-approved drug for Rett syndrome (DAYBUE®).
Listed vial contents: 100mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Trofinetide (NNZ-2566) is a synthetic analog of glycyl-L-prolyl-L-glutamate (GPE), the natural N-terminal tripeptide cleavage product of IGF-1 in the central nervous system. It is mechanistically distinct from intact IGF-1: rather than acting through the IGF-1 receptor, it modulates astrocyte / microglial activation, normalizes dendritic spine density, restores synaptic plasticity, and reduces neuroinflammatory cytokine signaling in animal models of neurodevelopmental injury. The molecule is orally bioavailable, crosses the blood–brain barrier, and is stable to enzymatic degradation that rapidly clears native GPE.
What are the research questions?
- Rett syndrome: FDA-approved March 2023 as DAYBUE® (Acadia Pharmaceuticals) for treatment of Rett syndrome in patients ≥2 years — the first approved therapy for the disorder.
- Fragile X syndrome: Phase 2 trials investigated trofinetide for behavioral and cognitive endpoints in Fragile X.
- Neurodevelopmental research: Used in preclinical models of MeCP2-deficient and other neurodevelopmental disorders to study synaptic-plasticity rescue.
- Traumatic brain injury research: Original development indication; preclinical data demonstrated reductions in lesion volume and improved functional recovery.
What does the published work describe?
Neul JL et al. (Nat Med 2023, LAVENDER trial) — Phase 3 demonstrated statistically significant improvement vs placebo on the Rett Syndrome Behaviour Questionnaire and Clinical Global Impression-Improvement at 12 weeks. FDA approval March 2023.
What are the limits of this evidence?
The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.
Study references
- Neul JL et al. Nat Med 2023 — LAVENDER Phase 3
- Glaze DG et al. Neurology 2019 — Phase 2 Rett
- Bickerdike MJ et al. J Neurol Sci 2009 — NNZ-2566 TBI preclinical
These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Trofinetide (NNZ-2566) handled in the lab?
For Trofinetide (NNZ-2566), record the product code TROF-100, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for Trofinetide (NNZ-2566) from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
For Trofinetide (NNZ-2566), calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists 341.4 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Trofinetide (NNZ-2566) form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Trofinetide (NNZ-2566) laboratory protocol should record identity, product code TROF-100, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Trofinetide (NNZ-2566)
- CAS Number
- 853400-76-7
- Molecular Weight
- 341.4 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- Cognitive
- Starting Price
- $129.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Trofinetide (NNZ-2566) has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Trofinetide (NNZ-2566)?
Trofinetide (NNZ-2566) is listed for tripeptide neurobiology research. Catalog vial contents are 100mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Trofinetide (NNZ-2566) are available?
The catalog lists 100mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Trofinetide (NNZ-2566) purity results?
Trofinetide (NNZ-2566) has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Trofinetide (NNZ-2566) be handled in the laboratory?
For Trofinetide (NNZ-2566), record the product code TROF-100, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Trofinetide (NNZ-2566)?
Choose a solvent for Trofinetide (NNZ-2566) from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
How do I calculate a Trofinetide (NNZ-2566) stock concentration?
For Trofinetide (NNZ-2566), calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists 341.4 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Trofinetide (NNZ-2566) be stored after preparation?
Use the documented storage conditions for the supplied Trofinetide (NNZ-2566) form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Trofinetide (NNZ-2566) lab protocol document?
A Trofinetide (NNZ-2566) laboratory protocol should record identity, product code TROF-100, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Trofinetide (NNZ-2566) product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this Trofinetide (NNZ-2566) lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is Trofinetide (NNZ-2566) for human use?
No. Trofinetide (NNZ-2566) is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
